EGFR and non-small cell lung carcinoma: This real-world, multicenter study of Thai patients with locally advanced NSCLC demonstrates that durvalumab consolidation therapy following definitive chemoradiotherapy achieved favorable clinical outcomes consistent with the PACIFIC trial, despite including diverse patient populations with EGFR mutations and suboptimal characteristics typically underrepresented in registration trials.